埃利斯波特
免疫学
人类白细胞抗原
T细胞
抗原
医学
免疫系统
细胞毒性T细胞
免疫疗法
癌症免疫疗法
乳腺癌
表位
肽疫苗
树突状细胞
癌症
生物
内科学
体外
生物化学
作者
Takafumi Morisaki,Makoto Kubo,Shinji Morisaki,Masayo Umebayashi,Hiroto Tanaka,Norihiro Koya,Shinichiro Nakagawa,Kenta Tsujimura,Sachiko Yoshimura,Kazuma Kiyotani,Yusuke Nakamura,Masafumi Nakamura,Takashi Morisaki
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2024-12-17
卷期号:16 (24): 4204-4204
被引量:2
标识
DOI:10.3390/cancers16244204
摘要
Background/Objectives: Neoantigens have attracted attention as ideal therapeutic targets for anti-tumour immunotherapy because the T cells that respond to neoantigens are not affected by central immune tolerance. Recent findings have revealed that the activation of CD4-positive T cells plays a central role in antitumor immunity, and thus targeting human leukocyte antigen (HLA) class II-restricted neoantigens, which are targets of CD4-positive T cells, is of significance. However, there are very few detailed reports of neoantigen vaccine therapies that use an HLA class II-restricted long peptide. In the present study, we retrospectively analysed the ability of HLA class II-restricted neoantigen-pulsed dendritic cell vaccines to induce immune response in five breast cancer patients. Methods: We performed whole exome and RNA sequencing of breast cancer tissues and neoantigen prediction using an in silico pipeline. We then administered dendritic cells pulsed with synthesized an HLA class II-restricted long peptide containing an epitope with high affinity to HLA class I in the lymph node. Results: ELISPOT analysis confirmed that a T-cell response specific for the HLA class II-restricted neoantigen was induced in all cases. TCR repertoire analysis of peripheral blood mononuclear cells before and after treatment in three patients showed increases of specific T-cell clones in two of the three patients. Importantly, no recurrence was observed in all patients. Conclusions: Our analysis demonstrated the immunological efficacy of the HLA class II-restricted neoantigen peptide dendritic cell vaccine against breast cancer and provides useful information for the development of neoantigen vaccine therapy for breast cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI